The development of novel and effective treatment strategies, particularly through drug combinations, can significantly enhance therapeutic outcomes. This study explores the innovative combination of
We describe several new aromatic nitrogen mustards with various aromatic substituents and boronic esters that can be activated with H2O2 to efficiently cross-link DNA. In vitro studies demonstrated th
The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodomain extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two mos
The moderate-to-high in vitro cytotoxicity against ovarian A2780 (IC50 = 4.7–14.4 μM), prostate LNCaP (IC50 = 18.7–30.8 μM) and prostate PC-3 (IC50 = 17.6–42.3 μM) human cancer cell lines of the plati
PIK3CA, which encodes the p110α catalytic subunit of PI3Kα, is frequently mutated in a variety of cancers. Consequently, targeting PI3Kα using a small-molecule inhibitor represents a key therapeutic s
